ArticleJournal of neurosurgery. Case lessons2025
Rapid response to BRAF/MEK inhibitor therapy within 2 weeks for high-grade glioma with leptomeningeal metastasis: illustrative case.
Article in Journal of neurosurgery. Case lessons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-grade gliomas, particularly isocitrate dehydrogenase-wildtype glioblastomas (GBMs), are highly aggressive brain tumors with limited treatment options and poor outcomes. A subset of these tumors, including epithelioid GBM, can harbor the BRAF V600E mutation, which drives tumor growth via persistent activation of the RAS/MAPK signaling pathway. Recently, the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) has been approved for treating inoperable solid tumors with this mutation. OBSERVATIONS: The authors present the case of a 51-year-old man with epithelioid GBM harboring the BRAF V600E mutation who developed early leptomeningeal metastasis (LMM) following standard therapy with surgery, temozolomide, and radiotherapy. Owing to disease progression, he was treated with dabrafenib and trametinib. Remarkably, the patient showed rapid clinical and radiographic improvement within 2 weeks of treatment initiation. MR images demonstrated significant reduction in tumor-associated edema and contrast enhancement. At the 28-week follow-up, the patient achieved near-complete radiographic remission without notable adverse effects. LESSONS: This case highlights the potential of BRAF/MEK inhibitor therapy to significantly improve outcomes in patients with aggressive gliomas and LMM, conditions typically associated with extremely poor prognosis. Further studies are needed to validate the long-term efficacy and safety of this targeted therapeutic approach in similar cases. https://thejns.org/doi/10.3171/CASE25247.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.